This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 May;140(5):1687-8.

doi: 10.1053/j.gastro.2011.03.034. Epub 2011 Mar 24.

The search for an effective partner for sorafenib: the failure of doxorubicin

Maria Reig¹, Jordi Bruix

Affiliations

PMID: 21439982
DOI: 10.1053/j.gastro.2011.03.034

Comment

The search for an effective partner for sorafenib: the failure of doxorubicin

Maria Reig et al. Gastroenterology. 2011 May.

. 2011 May;140(5):1687-8.

doi: 10.1053/j.gastro.2011.03.034. Epub 2011 Mar 24.

Authors

Maria Reig¹, Jordi Bruix

Affiliation

¹ BCLC Group, Liver Unit, Hospital Clinic, CIBERehd, Barcelona, Spain.

PMID: 21439982
DOI: 10.1053/j.gastro.2011.03.034

No abstract available

PubMed Disclaimer

Comment in

Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer.
Abou-Alfa GK, Saltz LB. Abou-Alfa GK, et al. Gastroenterology. 2011 Sep;141(3):e19-20; author reply e20-1. doi: 10.1053/j.gastro.2011.04.063. Epub 2011 Jul 24. Gastroenterology. 2011. PMID: 21794834 No abstract available.

Comment on

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Abou-Alfa GK, et al. JAMA. 2010 Nov 17;304(19):2154-60. doi: 10.1001/jama.2010.1672. JAMA. 2010. PMID: 21081728 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science